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Abstract. The available evidence indicates a high performance of core cerebrospinal fluid (CSF) biomarkers in differentiating
between Alzheimer’s disease (AD) and other dementias, and suggests that their characteristic alterations can be detected even
at the prodromal stage of AD. On this basis, the ability of core CSF biomarkers to identify prodromal AD patients from
pre-dementia of all causes can be postulated, a concept that is reflected in recent revisions of AD research criteria and a
consensus statement. Following an overview on the role of biomarkers in the evolution of diagnostic criteria of AD in recent
decades, this paper provides a critical review of the widely applied CSF biomarker study designs and evaluating approaches
that address the ability of core CSF biomarkers to diagnose prodromal AD, with special focus on their potential limitations in
terms of clinical interpretation and utility. The findings together raise the question of whether we are indeed able to establish
a CSF biomarker-based diagnosis of AD at the prodromal stage.
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INTRODUCTION20
Alzheimer’s disease (AD) is known to be the21
most prevalent neurodegenerative disease worldwide,22
accounting for the highest proportion (∼60%) of all-23
cause dementia. The most representative pathological24
hallmarks of the disease were described by the Ger-25
man neuropathologist Alois Alzheimer as early as26
1906, detecting neurofibrillary tangles and the extra-27
cellular formation of amyloid plaques together with28
the substantial shrinkage of the brain of a patient who29
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ment of Neurology, University of Szeged, H-6725 Szeged,
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died of a peculiar condition with a presenile deterio- 30
ration of cognitive functions, especially affecting the 31
memory. More than a century later, although substan- 32
tial advances have been achieved in the understanding 33
of the nature and pathophysiological background of 34
the disease, we still do not have any therapeutic tool 35
in hand with evidence to indicate that it is capable of 36
even influencing the disease course. At the expense 37
of an armada of clinical trials that have failed to prove 38
the therapeutic effect of their candidates having been 39
successful in preclinical settings, a novel concept has 40
started to take shape as to how we should view AD 41
and related disorders, and, more importantly, what we 42
should regard as AD. This review paper summarizes 43
the current understanding of the pathophysiology of 44
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AD with special focus on the biological markers45
(biomarkers) of core pathophysiological alterations46
and their effect on our view on patients with cogni-47
tive decline and dementia. A critical overview is given48
here of the most typical study designs and evaluation49
approaches as regards the diagnostic accuracy and50
potential of core cerebrospinal fluid (CSF) biomark-51
ers in differentiating AD from other etiologies at52
both the dementia and pre-dementia (i.e., prodromal)53
stages.54
HALLMARK PATHOPHYSIOLOGICAL55
ALTERATIONS56
The most representative pathological alterations57
in AD include the region-selective synaptic and58
neuronal degeneration, deposition of extracellular59
amyloid consisting predominantly of an amyloid-60
protein isoform with a length of 42 amino acids61
(A42) responsible for the formation of neuritic62
plaques, diffuse plaques, cored plaques, subpial63
bands, and amyloid lakes, and the accumulation of64
hyperphosphorylated microtubule-associated protein65
Tau (pTau) in neuronal cells, leading to the formation66
of neurofibrillary tangles (NFTs) [1–3]. The preferen-67
tially affected brain territories include the entorhinal,68
hippocampal, temporal, and neocortical association69
areas, with the earliest and dominant psychologi-70
cal sign being the disturbance of episodic memory.71
While the association of the above changes in AD72
is apparent, the causative relationships between the73
alterations are subjects of extensive discussion.74
The amyloid hypothesis holds that the increased75
presence of A42 in the brain formed by the cleav-76
age of amyloid- protein precursor (APP) via the77
consecutive functions of - and -secretases (this78
is also known as the amyloidogenic cleavage path-79
way) is the primary pathogenic factor in the cascade80
of events leading to NFT formation and subsequent81
neuronal degeneration [4]. A42 is prone to self-82
aggregate to soluble oligomers of different sizes,83
which have been widely demonstrated to be toxic to84
synapses and neurons, accounting for the majority85
of amyloid-related toxicity [5], with mitochondrial86
dysfunction and glutamate-mediated excitotoxicity87
being heavily implicated [6, 7]. A42 also readily88
aggregates to -sheets to form insoluble fibrils and89
eventually plaques, which probably serve as a reser-90
voir for toxic soluble forms and appear to be locally91
neurotoxic [8]. Furthermore, a body of experimen-92
tal evidence supports the hypothesis that amyloid93
oligomers per se drive the hyperphosphorylation of 94
Tau [9–13], providing a pathomechanistic rationale 95
for A being a primary etiological factor in the cas- 96
cade of AD pathophysiological process. Notably, the 97
plaque burden itself appears to correlate poorly with 98
disease severity and cognitive impairment [14, 15], 99
and A plaque pathology is frequently found among 100
the elderly without a symptomatic cognitive decline 101
[16–23], also supporting an indirect role of amyloid 102
deposition in neurodegeneration. 103
Microtubule-associated protein Tau is proposed to 104
stabilize axonal microtubules and promote axonal 105
function in a process regulated largely by the phos- 106
phorylation state of Tau by multiple phosphatases 107
and kinases [24]. In AD, the rate of phosphoryla- 108
tion is abnormally high. Hyperphosphorylated Tau 109
(pTau) is in turn prone to detach from microtubule 110
proteins, resulting in the loss of axonal integrity and 111
the cytosolic accumulation and aggregation of pTau 112
in the form of paired helical filaments, which leads to 113
the formation of NFTs and dystrophic neurites, ulti- 114
mately rendering the affected neurons to degenerate 115
and die [25]. The degree of neuronal loss and dis- 116
ease severity has generally been found to correlate 117
better with Tau pathology than with amyloid plaque 118
burden [14–16, 26]. Though alternative triggers such 119
as mitochondrial dysfunction [27], oxidative stress 120
[28], excitotoxicity, and neuroinflammation [29] have 121
also been proposed, hyperphosphorylation of Tau 122
is generally thought to be triggered by and there- 123
fore downstream of the amyloid pathology in the 124
disease continuum, and the biochemical fingerprints 125
of these pathologies are generally detectable in a 126
timeline corresponding with this hypothesis [30]. 127
However, recent publications of Braak and colleagues 128
report a substantially earlier presentation of Tau 129
histopathology especially in the subcortical areas of 130
the brain as compared with the amyloid pathology 131
[31, 32], whereas others have described a proportion 132
of patients presenting with signs of neurodegenera- 133
tion prior to the appearance of amyloid pathology via 134
imaging modalities [33], observations which leave 135
this question open for further discussion. 136
Although AD is characterized neuropathologically 137
by the presence of amyloid plaques and NFTs in 138
the predisposed brain areas affected by neurodegen- 139
eration, there is considerable evidence that elderly 140
people can present with substantial amyloid as well 141
as Tau pathology on autopsy without any signs of 142
cognitive involvement detected antemortem [16–23]. 143
Whereas such observations may theoretically suggest 144
that the pathology defined as AD-type might not be 145
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sufficiently specific to AD, the currently available146
evidence indicates that such cases might represent147
preclinical (or clinically inappropriately phenotyped148
prodromal) stages of AD at death, which would have149
progressed into AD dementia provided they had lived150
long enough [34]. This concept is similar to the151
one that regards incidental Lewy-body disease as a152
presymptomatic phase of Parkinson’s disease (PD)153
[35]. The picture has become even more complicated154
with the increasing recognition of the substantial155
heterogeneity of neuropathological alterations not156
only among the non-demented elderly [16], but157
also among patients with hippocampal-type demen-158
tia accompanied by a dominant AD-type pathology159
[1]. Indeed, neuropathological substrates of vascu-160
lar dementia (lacunary infarctions and white matter161
lesions as the most frequent concomitants [36]),162
frontotemporal lobar degeneration (FTLD; differen-163
tially localized NFTs and TDP-43 inclusions), diffuse164
Lewy-body disease (DLBD; -synuclein deposits),165
PD (-synuclein deposits pathognomically in the166
substantia nigra pars compacta), hippocampal scle-167
rosis, and argyrophilic grain disease are those that168
most commonly coincide with AD-type pathology169
in brains with ‘probable AD’ clinical phenotype [1],170
with a proposed rate of neuropathologically ‘pure171
AD’ of less than 60% [37]. At least in part due to172
this underlying heterogeneity, the differential diagno-173
sis of such conditions is often challenging, especially174
in cases of slowly progressive dementias with insid-175
ious onset. The real life importance of this issue is176
well indicated by data reporting the positive predic-177
tive value of the clinical diagnosis of AD as 70–81%178
when the endpoint includes AD as well as concomi-179
tant pathological conditions, decreasing to 38–44%180
when the evaluation is restricted to ‘pure’ AD cases181
[38]. In a more recent study in which the permissive182
threshold level for histopathological severity method183
was used to define autopsy-confirmed AD, i.e., a184
level considered sufficient to attribute to dementia185
irrespective of concomitant findings, the positive pre-186
dictive value of clinically ‘probable AD’ diagnosis187
was 62.2–83.3% with corresponding sensitivities and188
specificities of 70.9–76.6% and 59.5–70.8%, respec-189
tively (the values depended on the applied minimum190
threshold levels of histopathological severity, with191
more permissive neuropathological definitions result-192
ing in higher predictive value and specificity, and193
lower sensitivity) [39].194
The issue of low accuracy values for clinical diag-195
nosis in AD is of crucial importance in the setting196
of clinical trials, where the enrollment of clinically197
misdiagnosed patients or those with mixed pathology 198
1) seriously biases the statistical analysis, decreas- 199
ing the power of the study to confirm a therapeutic 200
effect, 2) raises the expense of the trials by treating 201
an unnecessarily high number of patients [40], and 3) 202
gives rise to ethical concerns as patients with different 203
etiological background should not hope for a rem- 204
edy from treatment approaches selectively targeting 205
AD-related pathomechanisms. All these di ficulties 206
underpin the critical need for markers that reflect the 207
underlying pathology with high accuracy in vivo, and 208
are facile, standardized, and cost-effective enough 209
for research and eventually for clinical use. In the 210
past two decades, extensive efforts have been made 211
worldwide to meet this need. 212
BIOCHEMICAL FINGERPRINTS OF 213
CORE PATHOLOGICAL ALTERATIONS 214
IN AD 215
The increasing recognition that amyloid and 216
Tau/pTau pathologies are leading hallmarks in the 217
pathogenesis of AD led to the discovery of their bio- 218
chemical correlates in the CSF some 20–22 years 219
ago [41–46]. Indeed the CSF level of A42 has 220
been found to be decreased by some 50%, and the 221
levels of Tau and pTau to be elevated by some 222
250–300% in AD as compared with non-demented 223
healthy individuals in multiple independent stud- 224
ies [47]. This constellation of alterations has often 225
been referred to as ‘the AD signature’, ‘the AD CSF 226
biomarker profile’, or briefly ‘the AD profile’, and 227
the three markers are often referred to as ‘the core 228
biomarkers’ of AD. Although the exact reason for 229
the decreased CSF concentration of A42 has not 230
yet been fully elucidated, the increased formation 231
of oligomers and their sequestration in the form of 232
insoluble aggregates in the brain (thus the charac- 233
teristic imbalance in the amyloid homeostasis) are 234
generally thought to be attributable to the decrease 235
in the monomeric form measured. The elevation of 236
CSF Tau is thought to reflect axonal/neuronal degen- 237
eration and injury, whereas that of pTau most likely 238
mirrors the kinase/phosphatase imbalance character- 239
istic of the disease. The observed alterations appear to 240
correlate well with autopsy findings [48–52], though 241
contrasting reports have also been published [53]. In 242
line with these, the diagnostic application of the above 243
CSF alterations individually provide 79–86% sensi- 244
tivity and 79–92% specificity when differentiating 245
between AD subjects and healthy controls, with even 246
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higher values if used in combinations (85–94% sen-247
sitivity, 83–100% specificity) [54–56]. Notably, the248
individual specificity of these markers substantially249
decrease when the aim is to differentiate between250
AD and non-AD dementia (NONAD) (66–86%) [55].251
Indeed, decreased CSF levels of A42 have also been252
described in dementia with Lewy bodies (DLB) [57,253
58], frontotemporal dementia (FTD) [59], and major254
depression [60], whereas elevated levels of Tau have255
been detected in multiple central nervous system256
(CNS) diseases associated with overt neuronal loss257
such as ischemic stroke [61], traumatic brain injury258
[62], DLB (though lower than in AD [57, 58, 63]),259
FTD [64], normal pressure hydrocephalus [65], and260
most prominently in Creutzfeldt-Jakob disease (CJD)261
[66]. The elevation of pTau is considered to be more262
specific to AD [67–69], even though the cytosolic263
aggregation of pTau filaments leading to NFT forma-264
tion are characteristic of all tauopathies. In addition265
to these, a number of studies have proposed ele-266
vated levels of Tau proteins as well as alterations267
in A42 levels in the CSF of patients with multi-268
ple sclerosis, which findings, however, could not be269
confirmed by our group, among others [70]. Notably,270
whereas the individual markers fail to provide suf-271
ficient specificity to accurately distinguish between272
different forms of dementia, their combined applica-273
tion demonstrates median specificity and sensitivity274
values > 85% across multiple studies [71–82] and in275
a recent systematic review [55], suggestive of reach-276
ing the threshold of meeting the established criteria277
for the minimum required accuracy of biomarkers278
for clinical differential diagnosis [83, 84]. While279
this is indeed an advancement relative to the lower280
specificity values obtained from the purely clinical281
diagnosis of ‘probable AD’ alone, the true merit of282
a marker (or a panel of markers) would be the accu-283
rate identification of individuals who are at risk of284
developing AD dementia, but are either in prodro-285
mal (with cognitive changes suspicious of being due286
to AD, not yet demented) or asymptomatic (with-287
out cognitive impairment) stages of the disease at the288
time of sampling. This is of crucial importance as289
regards the designing of clinical trials, as the pathol-290
ogy of patients with full-blown AD dementia might291
be overly severe to be therapeutically influenced in292
a clinically meaningful extent. In line with this con-293
cept, current clinical trials tend to focus on patients294
with mild cognitive impairment (MCI) who are con-295
sidered to be at risk of developing AD dementia in the296
future. It is reasonable that the selective enrollment of297
MCI patients harboring the biochemical fingerprints298
of the underlying pathology of AD could decrease 299
the bias due to the overlapping phenomenology of 300
pre-dementias. In this respect, a huge effort has been 301
placed on a series of longitudinal follow-up studies 302
evaluating the performance of the individual and/or 303
combined use of core CSF biomarkers in predicting 304
conversion of MCI patients to dementia (i.e., reaching 305
the threshold of interfering with daily functioning) 306
during their follow-up periods. While some of these 307
studies have demonstrated promising sensitivity and 308
specificity values (>80–85%) for the combined use of 309
core CSF biomarkers [85–89], there are several limi- 310
tations which must be taken into consideration when 311
interpreting or meta-analyzing thei performance in 312
distinguishing between AD and NONAD at the pro- 313
dromal stage, which will be specifically addressed in 314
the upcoming sections. However, important informa- 315
tion can be gleaned from theses analyses: Patients 316
with prodromal AD who develop CSF fingerprints of 317
both amyloid dyshomeostasis (i.e., A42 decrease) 318
and neurodegeneration (i.e., Tau and pTau elevation) 319
are in advanced disease stage, and the expected time 320
to develop a disabling condition (i.e., dementia) is 321
rather short, generally a few years [90]. This con- 322
cept is in accordance with the observation that CSF 323
A42 alteration may start earlier in the disease con- 324
tinuum, as in a longitudinal study with a median 325
follow-up of more than 9 years, the decrease in CSF 326
A42 was observable in both the converters (who 327
progressed into dementia of the AD-type) and the 328
non-converters within the MCI group, though to dif- 329
ferent extents, whereas substantially high levels of 330
Tau or pTau were present only among early converters 331
(conversion within 0–5 years), but not in late convert- 332
ers (conversion within 5–10 years) [89]. This appears 333
to be in homology with findings on patients with auto- 334
somal dominantly inherited familial AD, reporting 335
the appearance of a decreased CSF A42 and an ele- 336
vated CSF Tau to precede the expected symptomatic 337
onset by some 25 and 15 years, respectively [91]. 338
THE EMERGENCE OF IMAGING 339
BIOMARKERS: A BRIEF OVERVIEW 340
In parallel with the development of core bio- 341
chemical markers in the CSF, potential biomarkers 342
of different imaging modalities have been the sub- 343
jects of extensive research. Among them, positron 344
emission tomography (PET) CT scans involving the 345
use of 11C-labeled Pittsburgh compound B (PiB) 346
[92] or the more recently developed 18F radiotracers 347
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(florbetapir, flutemetamol, and florbetaben, among348
others [93]) as ligands are increasingly used to detect349
amyloid aggregate deposition in the brain, showing350
a rather good concordance with postmortem amy-351
loid burden [94–97] and also with alterations related352
to CSF A42 or A42/(p)Tau ratios [98–107]. Fur-353
thermore, the accuracy of amyloid PET was found354
comparable to that of CSF A42/Tau or A42/pTau355
ratios in a most recent study in differentiating pro-356
dromal AD patients from healthy controls, with no357
additional benefit when the two modalities were358
used together [108]. Likewise amyloid pathology at359
autopsy, both positive PET findings and decreased360
CSF A42 levels may accompany patients without361
cognitive decline, which may be regarded as cases362
in the preclinical phase of the AD continuum [107].363
Notably, however, most recent results suggest that364
CSF A42 decrease and amyloid PET retention rep-365
resent different aspects of amyloid pathology [105,366
109] and actually measure different forms of amy-367
loid, i.e., monomeric in the CSF versus aggregated368
fibrils by the tracers in the CNS. More recently,369
a number of PET ligands for the in vivo detec-370
tion of Tau pathologies have also been recently371
developed, the diagnostic applicability of which is372
under extensive research [67]. Of note, the ability373
of 2-(1-{6-[(2-(18)F-fluoroethyl)(methyl)amino]-2-374
naphthyl}ethylidene)malononitrile (18F-FDDNP), a375
PET tracer previously widely used to visualize both376
amyloid and Tau pathologies in the brain, has recently377
been questioned [110].378
Other forms of CT-based imaging modalities379
widely used in AD research include 18F-fluorode-380
oxyglucose (FDG) PET-CT to measure decreased381
glucose metabolism indicative of cellular dysfunction382
and loss [111, 112], and single-photon emission CT383
(SPECT) to measure cerebral hypoperfusion [113,384
114]. In both modalities, the typical brain regions385
detected to be predominantly involved in AD are the386
temporoparietal cortices. Magnetic resonance imag-387
ing (MRI) technology is a widely available modality388
utilized to rule out concomitant vascular or inflamma-389
tory etiology and to assess the characteristic atrophy390
of the medial temporal lobe (MTL) [115], an alter-391
ation that reflects regional neuronal loss in AD.392
Although the MTL (more specifically the entorhi-393
nal cortex and the hippocampus proper) is a region394
classically associated with MRI alterations in AD,395
the significant involvement of subcortical gray mat-396
ter structures [116–118] along with the alterations397
of white matter microstructure [119–122] have also398
been recently emphasized. The in-depth presentation399
of the different imaging modalities is beyond the 400
scope of this paper, and they have been extensively 401
reviewed by others [123]. 402
THE EVOLUTION OF DIAGNOSTIC 403
CRITERIA IN AD 404
Back in 1984, the National Institute of Neu- 405
rological and Communicative Diseases and 406
Stroke/Alzheimer’s Disease and Related Disorders 407
Association (NINCDS-ADRDA) published the 408
criteria for the definition of AD, which remained the 409
most widely applied diagnostic criteria in clinical 410
trials for some 27 years to come [124]. The NINCDS- 411
ADRDA recognized AD as a dementia characterized 412
by an amnestic syndrome of hippocampal type with 413
an insidious onset, and postulates that the diagnosis 414
is probabilistic when the patient is alive (probable 415
AD), whereas definite diagnosis could only be 416
provided by autopsy (definite AD). The subsequent 417
remarkable advances achieved in the fields of both 418
biochemical and imaging biomarkers as well as the 419
serial failures of clinical phase II and III trials to 420
provide confirmation of the therapeutic effect of 421
preclinically successful agents necessarily raised the 422
demand for the innovation of the long-standing clin- 423
ical diagnostic criteria of AD. As a result, in 2007, 424
the International Working Group (IWG) for New 425
Research Criteria for the Diagnosis of Alzheimer’s 426
Disease published a position paper with proposed 427
revised research criteria for probable AD [125]. Its 428
core clinical criterion is the presence of progressive 429
specific episodic memory impairment, whereas the 430
recommendation incorporated the abnormalities 431
of core CSF biomarkers in the supportive criteria, 432
together with the presence of MTL atrophy, a char- 433
acteristic PET pattern or an established autosomal 434
dominant mutation within the immediate family. 435
The paper proposes that the diagnosis of AD can 436
be established in the presence of the core clinical 437
criterion and at least one of the supportive criteria, 438
and in the absence of exclusive criteria [127]. The 439
main novelty in this concept is that it regards AD as a 440
disease continuum and it permits the diagnosis of AD 441
even in a prodromal phase, potentially based upon 442
the support of core CSF biomarkers. A refinement 443
for these criteria with a new lexicon of terms related 444
to AD, including ‘presymptomatic AD’, ‘asymp- 445
tomatic AD’, and ‘Alzheimer’s pathology’, was 446
published by the same group in 2010 [126]. One year 447
later, the National Institute on Aging–Alzheimer’s 448
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Association (NIA–AA) workgroups published an449
update on the clinical diagnostic recommenda-450
tions of the NINCDS-ADRDA, incorporating CSF451
biomarkers in the guideline as well [127]. However,452
the guideline proposes that demented patients453
meeting the core clinical criteria of AD and having454
signs of AD pathophysiological process either in455
terms of alterations in core CSF biomarkers or as456
regards characteristic changes in PET and MRI can457
be regarded as ‘probable AD with evidence of AD458
pathophysiological process’, which feature only459
increases the certainty that AD is the underlying460
etiology of the patients’ dementia, but does not461
per se support the diagnosis. In the same year,462
an update was published by the same workgroups463
on the diagnostic research criteria for MCI [128],464
postulating that the evidence of (either CSF or465
imaging) biomarkers for both amyloid deposition466
and neurodegeneration yields ‘a high likelihood’467
that MCI is due to AD, whereas the likelihood is468
considered ‘intermediate’ when there is evidence469
for only one of these two biomarker categories.470
In contrast, the IWG published their most recent471
revision for the research criteria of AD in 2014472
[129] in a position paper postulating that ‘typical473
AD’ can be diagnosed at any stage of the disease474
continuum (either prodromal or dementia stages)475
when the core clinical criteria are accompanied by in476
vivo evidence of AD, including either the presence477
of ‘the CSF AD signature’ (i.e., the AD profile),478
increased amyloid PET tracer retention, or a proven479
mutation of an autosomal dominant familial AD480
gene (structural MRI and FDG-PET alterations were481
no longer included due to insufficient specificity).482
Focusing on core CSF biomarkers, the paper argues483
that the CSF AD signature has high accuracy in484
diagnosing AD at a prodromal stage, with ∼90%485
specificity and sensitivity in AD. In line with this,486
the Alzheimer’s Diseases Standardization Initiative487
published a consensus paper stating that ’changes in488
A42, Tau, and pTau allow diagnosis of AD in its489
prodromal stage’, since ‘when all three classical AD490
CSF biomarkers are abnormal, a patient with MCI491
should be defined as having prodromal AD’ [130].492
LIMITATIONS FOR CLINICAL493
INTERPRETATION494
The following sections provide a critical review495
of the scientific background that promoted the evo-496
lution of the diagnostic criteria of AD, with special497
focus on the possible limitations of distinct types of 498
CSF biomarker studies that aim to assess the differen- 499
tial diagnostic performance of core CSF biomarkers 500
in the prodromal phase. Focus is not placed herein 501
on but recognition is expressed of the enormous 502
efforts of the Alzheimer’s Disease Association Qual- 503
ity Control program [131, 132], the Penn Biomarker 504
Core of Alzheimer’s Disease Neuroimaging Initiative 505
(ADNI) [30], the Alzheimer’s Biomarker Standard- 506
ization Initiative [130, 133], the Global Biomarker 507
Standardization Consortium (GBSC) [134], and the 508
early cNEUPRO [135] in the field of the elaboration 509
and standardization of pre-analytical and analyti- 510
cal protocols of CSF biomarker measurements in 511
AD for different analytical platforms, including the 512
singleplex ELISA tests and the multiplex Luminex 513
xMAP and Inno-Bia Alzbio3 immunoassay. Their 514
joint efforts will certainly move biomarker develop- 515
ment closer to overcoming current methodological 516
limitations such as the significant inter-laboratory 517
variability and the lack of CSF-based standard ref- 518
erence material, which will undeniably promote the 519
establishment of the methodological basis for the 520
research and probably later clinical utility of CSF 521
biomarkers in the diagnostics of AD. 522
As described above, in recent updates of the 523
research diagnostic criteria for AD, arguments can 524
be found supported by numerous references that 525
scientific evidence is available indicating that CSF 526
biomarkers can distinguish AD patients from other 527
dementias with high accuracy, even at the prodro- 528
mal stage. To analyze the validity of these arguments, 529
we have systematically reviewed the literature in this 530
field, identified the main questions addressed, and 531
critically analyzed the most frequent approaches to 532
answer them in terms of their ability to provide appro- 533
priate answers. 534
CSF biomarker-related studies can generally be 535
divided into three categories. The first cross- 536
sectional-type group that examines differences 537
between the target disease (i.e., AD) and healthy 538
controls and estimates the diagnostic accuracy of 539
biomarkers to distinguish between them are out of 540
scope of this section. The second (from the current 541
perspective) more relevant type of study examines 542
differences between the target disease and related 543
disorders, in our case between AD and NONAD(s), 544
and estimates the diagnostic accuracy of biomarkers 545
to distinguish between them. This type of cross- 546
sectional studies will be referred to throughout 547
this chapter as ‘differential diagnostic studies’. The 548
third main group of studies examines the diagnostic 549
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AD                
one 
particular 
NONAD
AD mixed NONAD
Potential limitations of  accuracy values derived from AD vs NONAD study designs include:
1. Lack of autopsy validation of clinical diagnosis
2. Interpretation not adjusted to differential prevalences
3.a Questionable utility in the clinical context         3.b Disproportionate representation of 
diagnoses within the NONAD group
vs vs
Fig. 1. Limitations of cross-sectional differential diagnostic studies in terms of clinical interpretation.
accuracy of biomarkers to identify patients with MCI550
who have an AD pathological background or are at551
risk of converting to AD within a certain period of552
time. These studies are often dedicated to assess-553
ing the possibility of the prodromal diagnosis of AD,554
which is a topic of special importance for adequate555
patient enrollment in clinical trials to come. As such556
longitudinal studies use the conversion to dementia as557
a dichotomized outcome within the defined follow-558
up period in MCI patients, they will be collectively559
referred to as ‘conversion studies’.560
Differential diagnostic studies561
The majority of studies report sensitivity and562
specificity data, and less frequently predictive val-563
ues, likelihood ratios, C-indices, and the area under564
the receiver operating characteristic curve (AUROC)565
values to characterize the performance of CSF566
biomarkers in differentiating AD dementia from other567
dementias. Though such studies provide fairly high568
accuracy values and are therefore promising, they569
appear to have several limitations. First of all, a570
remarkable proportion of studies establish diagnostic571
groups based solely on clinical consensus diagnosis,572
without autopsy confirmation. Even if the diagnosis573
is blinded to the CSF results (which is not always the574
case), the approach of estimating accuracy values for575
biomarkers based on diagnoses uncertain enough to576
drive and urge the development of the same particu-577
lar biomarkers is on the edge of circular reasoning.578
Secondly, specificity values from these studies are579
obtained from diverse comparator groups ranging580
from isolated diseases (i.e., FTD, DLB, subcorti-581
cal vascular dementia, etc.) to NONAD as a whole,582
which makes their collective clinical interpretation583
rather difficult. From a clinical perspective, accuracy584
values obtained from one-to-one comparisons (per- 585
formed by a remarkable proportion of studies) can 586
be useful when the differential diagnosis of a certain 587
case has already been narrowed to AD versus one 588
particular other form of dementia; however, the true 589
predictive values in the real clinical context should 590
be estimated as values controlled for the distinct 591
prevalence rates of AD and the respective compara- 592
tor condition, which adjusted values are usually not 593
provided by the studies themselves (Fig. 1). As in 594
a real clinical scenario, the differential diagnosis in 595
many cases cannot be narrowed to two conditions, a 596
real merit of CSF biomarkers would be to distinguish 597
AD from all other relevant conditions potentially 598
causing dementia, and accuracy values from studies 599
examining AD versus NONAD would therefore be 600
clinically helpful in the diagnosis (Fig. 1). In such 601
a scenario, however, valid specificity and thus pre- 602
dictive values could be provided only if the NONAD 603
group consisted of conditions that are represented in 604
proportions reflecting the relations of real life preva- 605
lence rates of the respective conditions, otherwise the 606
obtained specificity as well as other ‘negative-side’- 607
related parameters such as predictive values are fairly 608
biased, and are clinically less meaningful (Fig. 1). For 609
example, the overrepresentation of CJD (as a rare 610
differential diagnosis) within a NONAD group can 611
falsely increase the specificity value of the combined 612
use of CSF biomarkers, whereas the disproportion- 613
ally low presence of vascular dementia, for instance 614
(as a frequent differential diagnosis), could evoke the 615
opposite effect. In fact, studies assembling NONAD 616
groups from diverse conditions in proportions ade- 617
quately reflecting their relative prevalence rates in the 618
population are scarce. Once the comparator popula- 619
tion is representative in terms of its constitution, the 620
obtained predictive values should again be adjusted 621
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for the relative prevalence rates of AD versus the all-622
cause prevalence of the respective NONAD group to623
provide clinically meaningful and valid estimates.624
Conversion studies625
The main limitations of conversion studies are626
related in part to similar problematics as differen-627
tial diagnostic studies. In addition to the complete628
absence of autopsy-confirmed diagnoses, and the629
high variability of follow-up periods, a number of630
concerns are fundamentally related to study design.631
On the basis of the published conclusions, we have632
found that conversion-type studies typically address633
two questions (sometimes merged into one): 1) By634
how many years does the appearance of the complete635
(or partial) CSF AD profile precede the conversion to636
AD dementia in prodromal AD patients?; 2) To what637
accuracy can CSF biomarkers identify MCI patients638
who will eventually develop dementia due to AD639
(i.e., who have prodromal AD)?640
While the two questions are related, they are641
in fact slightly different entities, the first being a642
disease course-oriented question with in part patho-643
physiological interest, whereas the second being a644
prodromal differential diagnosis-oriented question645
with clinical interest, and their adequate answering646
requires slightly different study designs and evalua-647
tion approaches.648
As regards the first, disease course-oriented ques-649
tion, an idealistic study design would enroll MCI650
patients with CSF samples obtained at baseline,651
documenting their latency to convert to AD (or652
any other forms of dementia) during the follow-up,653
excluding patients not meeting the criteria of AD at654
autopsy as a standard of truth (less probably includ-655
ing patients with alternative clinical diagnosis but656
diagnosed as having AD at autopsy), and estimat-657
ing the frequencies of patients of complete or partial658
AD-type biomarker profiles (i.e., sensitivities) within659
subgroups stratified on the basis of well-defined inter-660
vals of the latency to convert into AD. This descriptive661
approach also enables the estimation of overall as662
well as latency-to-convert-adjusted sensitivity values,663
which have different roles in the interpretation of the664
diagnostic performance of CSF biomarkers (Fig. 2).665
We are aware of a single study that had a sufficiently666
long follow-up period (up to almost 12 years) to667
allow a similar way of stratification; its clinical diag-668
noses, however, have not yet been autopsy-confirmed669
[89]. To our knowledge, no conversion studies have670
yet been published with autopsy-validated diagnoses.671
The vast majority of studies estimate sensitivities for 672
the prediction of clinical conversion within signifi- 673
cantly shorter arbitrarily defined follow-up periods 674
(usually 1–3 years). 675
As regards the second, prodromal differential 676
diagnosis-oriented question, which aims to deter- 677
mine the accuracy of CSF biomarkers in predicting 678
the diagnosis of AD in the prodromal phase, an ide- 679
alistic study design would enroll consecutive MCI 680
patients with CSF samples obtained at baseline, fol- 681
lowing them up through their conversion of different 682
types of dementia (or remaining stable until death), 683
confirming (or overwriting) their clinical diagnoses 684
by autopsy as a standard of truth, and estimating the 685
diagnostic accuracy of CSF biomarkers to differenti- 686
ate between those who converted to AD (MCI-AD) 687
and those who converted to any other developed 688
forms of dementia (MCI-NONAD) pooled with the 689
group of patients who remained stable or in infrequent 690
cases became ‘backwashed’ to normal until death 691
(study design MCI-AD versus MCI-NONAD+MCI- 692
permanently stable, Fig. 2). This design provides a 693
realistic differential diagnostic situation in the pro- 694
dromal phase, is free from the uncertainty of clinical 695
diagnosis alone, and is theoretically free from the 696
bias of the potentially disproportionate representa- 697
tion of diagnoses within the MCI-NONAD group 698
(as compared with a potentially significant bias 699
addressed above regarding the cross-sectional ‘AD 700
versus NONAD’ studies) as the development of dif- 701
ferent types of dementias from a heterogeneous MCI 702
group with consecutive patients enrolled without any 703
a priori filtering is ideally random and follows the 704
natural prevalence rates of the diseases. A limita- 705
tion of this design is the uncertainty of the relative 706
contribution of a particular pathology in cases pre- 707
senting with mixed pathology at autopsy, an issue that 708
is especially relevant in cases with longer follow-up 709
duration and higher age at death. We are not aware 710
of any studies have yet been published with this 711
design. Instead, studies addressing this question can 712
be essentially divided into two subtypes (Fig. 3). Both 713
subtypes work with arbitrarily set follow-up periods 714
and without autopsy-validated diagnostic groups, as 715
the majority of enrolled patients are still alive. The 716
first subtype of study design estimates the diagnostic 717
accuracy of biomarkers to distinguish between MCI 718
patients who clinically convert to AD dementia (usu- 719
ally referred to as MCI-AD or MCI-C) and those who 720
remain stable during the follow-up period (usually 721
referred to as MCI-stable, MCI-NC, or MCI-MCI). 722
Notably, this ‘MCI-AD versus MCI-stable’ design, 723
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Fig. 2. An idealistic longitudinal study design for the determination of prodromal differential diagnostic performance of core CSF biomarkers
obtained from MCI patients at baseline. Dotted arc represents the time needed until all participating MCI cases achieve clinical diagnosis of
dementia of any type, reflecting both the probabilistic nature of the diagnosis and the uncertainty whether such a time-point can be determined
at all due to the presence of residual MCI-stable cases. The solid arc represents the time needed until all cases have definite neuropathological
verification or revision of their diagnoses. Autopsy-confirmed diagnosis enables the accurate estimation of the overall specificity by the use
of MCI-AD versus MCI-NONAD+MCI-permanently stable design. The graph depicting the frequencies of MCI-AD converters that had an
AD CSF biomarker profile at baseline delineates an expectable gradual decrease in the diagnostic sensitivity by the increase of the latency
to convert to AD dementia, which suggests a diagnostically insufficient overall sensitivity and the limitation of core CSF biomarkers to at
most predict early conversion to AD. AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; FTD; frontotemporal dementia; MCI,
mild cognitive impairment, VaD, vascular dementia; (. . . ), any other diagnosis including permanently stable cases.
an approach used in the majority of studies widely724
cited in support of the putative excellent accuracy725
of core CSF AD biomarkers in predicting the diag-726
nosis of AD even in the prodromal phase [59, 85,727
88, 136–148], has a severe and fundamental limi-728
tation in providing valid and clinically meaningful729
accuracy measures for prodromal differential diagno-730
sis, as it disregards the expectation that a remarkable731
proportion (∼20–40%) of converters would develop732
NONAD in a real-life situation, a group that is in fact733
missing from these analyses. The provided specificity734
value in studies using this design therefore does not735
reflect anything other than the ratio of patients with a736
negative CSF profile among non-converters, with no737
information about its relation with parallel-developed738
other dementias at all. In other words, the ‘MCI-AD739
versus MCI-stable’ design does not indeed identify740
prodromal AD, but only provides sensitivity values741
for the detection of early converters (Fig. 3). The 742
second and recently preferred way of estimating the 743
accuracy of CSF biomarkers in identifying prodromal 744
AD is more reminiscent of the idealistic approach 745
delineated above (Fig. 3). This approach recog- 746
nizes three groups at the end of follow-up, which 747
are converters to AD (MCI-AD), non-converters 748
(MCI-stable), and converters to a dementia other 749
than AD (MCI-NONAD), and analyzes them in 750
a study design comparing MCI-AD versus MCI- 751
stable+MCI-NONAD in the ROC analysis (the latter 752
pooled group is occasionally referred to collectively 753
as MCI-NONAD) [86, 87, 89, 149–154]. The study 754
with the longest follow-up period published to date 755
(median 9.2 years) reported the following distribu- 756
tion of diagnoses at evaluation: MCI-AD representing 757
77% of all dementia and 54% of all MCI; MCI- 758
NONAD representing 23% of all dementia and 16% 759
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MCI-stable                MCI-AD MCI-AD MCI-stable
Potential limitations of  accuracy values derived from conversion-type study designs include:
1. Lack of autopsy validation of clinical diagnosis
2. Highly variable follow-up periods and thus conversion rates
3. Estimates not not controlled for age and gender distribution
4. Dynamic heterogeneity of the MCI-stable group
5.a Omission of other dementias developed      5.b Note: identification, not differential diagnosis
vs vs
?
MCI MCI
MCI-
NONAD
Fig. 3. Limitations of longitudinal conversion studies in terms of clinical interpretation.
of all MCI (these stand for an overall 70% conver-760
sion rate); and MCI-stable representing 30% of all761
MCI [89]. In contrast, another study group with an762
overall 35–38% conversion rate from MCI patients at763
baseline within 2-3-year follow-up periods described764
a 89–92% versus 8–11% representation for MCI-765
AD and MCI-NONAD, respectively [149, 150]. The766
remarkable differences in the rate of conversion,767
which is a natural dependent of the established length768
of follow-up period and the disease duration at base-769
line sampling, and in the distribution of converters770
between MCI-AD and MCI-NONAD altogether sug-771
gest a high inter-study variability in terms of the772
predictive values of CSF biomarkers independently773
of the sensitivity and specificity characteristics of774
the biomarkers themselves, which should be taken775
into consideration during meta-analysis and collec-776
tive interpretation of the data (Fig. 3). This ‘MCI-AD777
versus MCI-NONAD+MCI-stable’ approach might778
indeed be useful and relevant when the aim is to enroll779
patients into clinical trials who are similar in terms of780
their expected latency to convert into dementia, and781
to identify prodromal cases in a late phase where CSF782
AD profile is established. It is also more proper com-783
pared to the ‘MCI-AD versus MCI-stable’ approach784
as their values related to the negative side (i.e.,785
specificity, predictive value, etc.) are clinically mean-786
ingful. Notably, however, the ability of this approach787
to accurately assess the differential diagnostic perfor-788
mance of biomarkers is still limited, since due to the789
heterogeneity of the MCI-stable group, a remarkable790
proportion of the MCI-NONAD+MCI-stable pooled 791
comparator group may indeed have AD as the under- 792
lying pathology at a prodromal stage as well (which 793
may as well be as high as 30–40% depending on 794
size of residual MCI-stable group and the length of 795
follow-up). Briefly, this approach does not literally 796
differentiate between prodromal AD and other pre- 797
dementias, but differentiates prodromal AD cases in 798
a fairly advanced stage from all other possible con- 799
ditions, including late converters to AD (Fig. 3). 800
Minor, but relevant additional concerns regarding 801
the conversion-type studies include the high chance 802
that the group of MCI patients who convert into 803
dementia during an a priori defined follow-up period 804
may happen to be significantly older than those who 805
do not convert to dementia, and/or have a higher 806
female/male ratio, with age and female gender being 807
significant risk factors of AD dementia. Though only 808
few studies address these issues specifically, such sce- 809
narios appear indeed quite often [85–87, 89, 106, 810
140, 151, 152, 155], whereas adjustment for these 811
confounders is usually performed in independent 812
multivariate Cox regression analyses, if at all, and 813
the diagnostic accuracy values themselves remain 814
frequently uncontrolled (Fig. 3). Another potential 815
limitation of conversion studies in terms of provid- 816
ing differential diagnostic estimates is the potentially 817
false presumption that all dementia diseases have 818
similar dynamics regarding the propensity to con- 819
vert; indeed, diseases with a slower conversion rate 820
(or later dementia onset) as compared with AD will 821
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be overrepresented in the MCI-stable group and vice822
versa, and consequently, the relative proportion of823
the different conditions within the MCI-stable group824
changes dynamically during the follow-up period825
(and therefore differs between studies with different826
follow-up lengths), factors which together add fur-827
ther uncertainty to the constitution of the MCI-stable828
group (Fig. 3).829
ARE WE ABLE TO ESTABLISH A830
PRODROMAL DIAGNOSIS?831
On the basis of the published data and recent832
systematic reviews suggesting a high accuracy of833
combined CSF biomarkers in differentiating between834
AD and different dementias and proposing that CSF835
AD profile can be detected in AD patients at a pro-836
dromal stage, the indirect conclusion can logically837
be drawn that these markers should have the abil-838
ity to differentiate prodromal AD patients from MCI839
patients with other etiological background. The need840
for a prodromal differential diagnosis of typical AD is841
indisputable, as it potentially represents a key for suc-842
cessful clinical trials. Indirect deductions, however,843
should be based on massive evidence.844
According to our critical review, diagnostic accu-845
racy data on the performance of combined CSF846
biomarkers to distinguish between AD and NONAD847
in the dementia phase in a cross-sectional design848
are biased to a certain extent, mainly owing to the849
paucity of autopsy validation and the frequently non-850
representative assembly of the NONAD groups in851
terms of real-life prevalence rates (Fig. 1). Never-852
theless, there may be arguments suggesting that the853
diagnostic performance of CSF biomarkers from this854
respect may still be comfortingly high. Since AD rep-855
resents the majority of dementia cases (∼60%; i.e.,856
the chance of a random demented patient having AD857
is higher relative to all other diagnoses altogether), the858
adjustment for the prevalence rates increases the pre-859
dictive values. The report proposing that the clinical860
diagnosis fairly underestimates the diagnosti perfor-861
mance of CSF biomarkers compared with autopsy862
diagnosis is also supportive in this respect [156]; how-863
ever, this observation was not confirmed by others864
[71].865
On the other hand, longitudinal conversion studies866
have likewise provided in part biased informa-867
tion about the predictive performance of the AD868
biomarker profile as regards early conversion to AD,869
which is mainly because of the omission of MCI-870
NONAD from the comparator group in the majority 871
of studies addressing this question (‘MCI-AD ver- 872
sus MCI-stable’ design; Fig. 3). While respecting the 873
incontestable clinical significance of studies using 874
the ‘MCI-AD versus MCI-stable+MCI-NONAD’ 875
design, it should be noted that such a design can- 876
not specifically address the differential diagnostic 877
accuracy due to the substantial heterogeneity of the 878
comparator groups (i.e., the ‘unstable’ MCI-stable 879
group; Fig. 3). Strictly speaking, the true differen- 880
tial diagnostic performance of CSF biomarkers in a 881
prodromal phase cannot be accurately estimated until 882
residual MCI-stable cases with the potential to con- 883
vert to AD later are present in the evaluation; the term 884
‘the accuracy of AD diagnosis at the prodromal stage’ 885
should therefore be used with caution, as the values 886
obtained from these studies at most refer to ‘the accu- 887
racy of identifying early converters to AD’. While 888
this distinction may sound academic, the two terms 889
are essentially different. This is because, while there 890
may indeed be a chance that the combined use of core 891
CSF biomarkers may identify early converters to AD 892
from all other possible outcomes, their overall differ- 893
ential diagnostic performance in the prodromal phase 894
can be prognosticated to be rather poor. Since Tau and 895
pTau elevations in the CSF appear to be preferentially 896
present in MCI patients within 5 years before clini- 897
cal conversion to dementia (i.e., in early converters) 898
and not in those who convert later (as opposed to the 899
relatively stable presence of decreased CSF A42 in 900
MCI) [89], the frequency of an altered CSF profile 901
in MCI-AD patients (i.e., the sensitivity) presumably 902
gradually decreases by the increase in the latency to 903
convert to dementia (Fig. 2). This suggests that the 904
overall sensitivity of the biomarker profile to identify 905
MCI-AD cases among all MCI patients is less than 906
it would be accepted as being of diagnostic value 907
(i.e., 85%). This theoretical concept of gradually 908
decreasing sensitivity is supported by the reported fall 909
in sensitivity value for the combination of Tau and 910
A42/pTau from the excellent 95% [86] to a diag- 911
nostically insufficient 82% by the extension of the 912
median follow-up with 4 years (from 5.2 to 9.2 years) 913
[89], whereas in another study by a fall in sensitivity 914
for the AD-like CSF pattern from 82.9% to 68.0% by 915
a 2-year extension of the follow-up (from 1 to 3 years) 916
[148]; furthermore, it is also confirmed by findings of 917
a comprehensive recent meta-analysis of conversion 918
studies estimating the differences between those with 919
a follow-up ≤ or > 1 year [90]. 920
In addition to the limitations of studies address- 921
ing the prodromal diagnosis of AD discussed above, 922
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Table 1
Diagnostic accuracy values and main characteristics of conversion studies reporting the combined use of core CSF biomarkers
Publication Biomarker§ Design Sensitivity Specificity Cohort Follow-up (y) Subject No. Method
Riemenschneider et al. [85] Tau and A42 MCI-AD versus MCI-stable 90.0% 90.0% German 1.5 28 ELISA
Herukka et al. [137] A42/pTau MCI-AD versus MCI-stable 60.9% 87.3% Finnish 3 78 ELISA
Hansson et al. [86] Tau and A42/pTau MCI-AD versus MCI-pooled 95.0% 87.0% Swedish 5.2 137 xMAP
Visser et al. [150]∗ Tau and A42 MCI-AD versus MCI-pooled 100.0% 38.5% DESCRIPA 3 100 ELISA
Mattsson et al. [151] Tau and A42/pTau MCI-AD versus MCI-pooled 82.6% 72.0% Swedish 3 750 ELISA & xMAP
Hertze et al. [87] Tau and A42 MCI-AD versus MCI-pooled 88.0% 82.0% Swedish 4.7 166 xMAP
Davatzikos et al. [142] Tau/A42 MCI-AD versus MCI-stable 86.8% 35.4% ADNI 1 120 xMAP
Cui et al. [147] Tau/A42 and pTau/A42 MCI-AD versus MCI-stable 80.4% 48.3% ADNI 2 143 xMAP
Parnetti et al. [88] A42/pTau MCI-AD versus MCI-stable 81.0% 95.0% Italian 3.4 90 ELISA
Vos et al. [149] A42/Tau MCI-AD versus MCI-pooled 83.0% 65.0% DESCRIPA & VUmc 2 153 ELISA
Buchhave et al. [89] A42/pTau MCI-AD versus MCI-pooled 88.0% 90.0% Swedish 9.2 137 xMAP
Liu et al. [146] Tau and A42 MCI-AD versus MCI-stable 57.0% 70.0% ADNI 3 199 xMAP
Westman et al. [148] AD profile of all three MCI-AD versus MCI-stable 68.0% 64.4% ADNI 3 162 xMAP
Gaser et al. [144] A42/pTau MCI-AD versus MCI-stable 92.0% 42.0% ADNI 3 195 xMAP
Toledo et al. [145] Tau/A42 MCI-AD versus MCI-stable 80.0% 46.2% ADNI 3 122 xMAP
Vos et al. [153] A42/Tau (aMCI) MCI-AD versus MCI-pooled 98.0% 38.0% DESCRIPA & VUmc 2.6 346 ELISA
A42/Tau (naMCI) MCI-AD versus MCI-pooled 90.0% 54.0% 2.4 192
Sierra-Rio et al. [154]‡ A42/pTau MCI-AD versus MCI-pooled 84.4% 81.6% Spanish 3 94 ELISA
§Biomarkers with the best performance within a study are indicated. ∗ Specificity value was unpublished but could be calculated based on the reported data. ‡ Sensitivity and specificity values
were unpublished but could be calculated from the reported data. MCI-pooled refers to the MCI-stable+MCI-NONAD design. Follow-up periods are indicated as means or medians. ADNI,
Alzheimer’s Disease Neuroimaging Initiative; DESCRIPA, Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s Disease; VUmc, VU University Medical
Center, Amsterdam, the Netherlands.
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Table 2
Diagnostic accuracy values for the individual and combined use of CSF AD biomarkers, stratified by the different study designs
Biomarker Study design n Sensitivity (%) Specificity (%)
A42 MCI-AD versus MCI-stable 9 73.13 (±5.99) 74.82 (±4.38) 66.83 (±8.74) 67.46 (±5.59)
MCI-AD versus MCI-pooled 5 77.86 (±6.43) 68.60 (±3.01)
Tau MCI-AD versus MCI-stable 11 72.10 (±5.11) 72.38 (±3.90) 64.42 (±5.92) 65.37 (±4.51)
MCI-AD versus MCI-pooled 4 73.15 (±5.23) 67.98 (±5.60)
pTau MCI-AD versus MCI-stable 10 77.73 (±2.24) 75.28 (±3.58) 70.54 (±6.18) 70.20 (±5.75)
MCI-AD versus MCI-pooled 2 63.05 (±21.1) 68.50 (±21.5)
Combination MCI-AD versus MCI-stable 9 77.34 (±4.19) 83.62 (±2.75) 64.29 (±7.53) 65.93 (±4.90)
MCI-AD versus MCI-pooled 9 89.89 (±2.15) 67.57 (±6.69)
The mean individual and combined sensitivities of CSF AD biomarkers are only slightly lower than that reported in meta-analyses assessing
studies with CSF samples obtained in the dementia phase, corresponding with the median follow-up period of 3 years and the expectation
that the complete CSF signature is present within 5 years before conversion to dementia [89]. However, the mean specificity values for both
the individual and combined biomarkers are ≤ 70%, far below diagnostic value. The obtained values are only slightly higher when analyzing
only studies using the more valid pooled design. Sensitivity and specificity data are presented as mean ± standard error of mean (SEM).
MCI-pooled refers to the MCI-stable+MCI-NONAD design. Bold values are obtained from joint analysis of studies with the two different
designs.
the highest concern regarding arguments stating that923
core CSF biomarkers could identify AD in a prodro-924
mal phase with high scientific accuracy is that there925
is at present no meta-analytic study to support them.926
Indeed, in the past year, Ferreira et al. published a927
comprehensive meta-analysis on the available data,928
and reported a good 85-86% sensitivity, but only929
a modest 60–79% specificity for the combined use930
of core CSF biomarkers in identifying prodromal931
AD, with the A42/pTau ratio providing the highest932
diagnostic performance; the meta-analysis, how-933
ever, jointly analyzed studies with ‘MCI-AD versus934
MCI-stable’ and ‘MCI-AD versus MCI-stable+MCI-935
NONAD’ designs [90]. This is in line with our own936
calculations with even higher number of relevant and937
additional recent studies included [85–89, 137, 142,938
144–151, 153, 154], yielding a mean sensitivity ∼939
85% (ranging 80–100%), but a mean specificity as940
low as <70% (ranging 35–95%) for the combined941
use of core CSF biomarkers in identifying prodromal942
AD, with only a slight improvement in specificity943
when separately analyzing studies with the ‘MCI-944
AD versus MCI-stable+MCI-NONAD’ design [86,945
87, 89, 149–151, 153, 154] (Tables 1 and 2, see946
methods in Supplementary Material). Even though947
our calculations are not of meta-analytic value, these948
data together with the recent meta-analysis suggest949
an insufficient diagnostic accuracy for core CSF950
biomarkers to identify prodromal AD, due to low951
specificity.952
CONCLUDING REMARKS953
The available accuracy data in the literature sug-954
gest a high performance of the combined use of core955
CSF biomarkers in differentiating between AD and 956
other dementias, and propose that their characteristic 957
alterations can be detected even at advanced prodro- 958
mal stages of AD. On this basis, it is tempting to 959
presume their ability to differentiate prodromal AD 960
patients from MCI patients of all causes, a concept 961
reflected by the recent revisions of AD research cri- 962
teria and a consensus statement. According to our 963
critical review on the widely applied study designs 964
and evaluating approaches, however, the available 965
evidence on the accuracy of CSF biomarkers in dif- 966
ferentiating between AD and other dementias as 967
well as in identifying MCI patients who convert into 968
AD dementia are biased mainly by a disproportion- 969
ate representation of differential diagnoses within 970
the NONAD group, the frequent non-adjustment 971
for confounders such as age and gender, the omis- 972
sion of MCI-NONAD cases from the analysis, the 973
potentially dynamic heterogeneity of the MCI-stable 974
group, and as a common source of confounders the 975
lack of autopsy confirmation of the clinical diagnosis. 976
Though unbiased direct evidence on the performance 977
of CSF biomarkers to distinguish between prodromal 978
AD and other pre-dementias is virtually absent, theo- 979
retical considerations in line with the reported data 980
suggest that the overall sensitivity may fall below 981
the acceptable value with the gradual extension of 982
follow-up. While accurate identification of early con- 983
verters to AD among MCI patients would per se 984
be of outstanding clinical relevance, the calculated 985
specificities from the currently available studies do 986
not reach the level of diagnostic accuracy, in line 987
with the results of a recent meta-analysis. While 988
further prospective studies with an unbiased evalu- 989
ation design and consecutive autopsy validation are 990
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eagerly awaited, at present there is no massive scien-991
tific evidence to support the use of CSF biomarkers992
in the differential diagnosis of prodromal AD, either993
in research or in clinical platforms.994
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